Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

999 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Semaglutide improves treatment satisfaction and eating behaviour in Japanese patients with type 2 diabetes mellitus.
Baba Y, Watanabe S, Hayashi S, Sakai T, Naka M, Kami S, Hirayama K, Koizumi K, Takahashi A, Meguro M, Iga R, Yamanaka Y, Kataoka M, Uchida D, Ishibashi R. Baba Y, et al. Among authors: yamanaka y. Diabetes Obes Metab. 2024 Oct;26(10):4787-4790. doi: 10.1111/dom.15823. Epub 2024 Aug 2. Diabetes Obes Metab. 2024. PMID: 39091271 No abstract available.
Impact of time to treatment initiation on the development of cachexia and clinical outcomes in lung cancer.
Katsushima U, Kurose S, Fukushima T, Nakano J, Ogushi N, Fujii K, Nagata Y, Kamisako K, Okuno Y, Okazaki Y, Nakanishi K, Yoshida K, Ikoma T, Takeyasu Y, Yamanaka Y, Yoshioka H, Hase K, Kurata T. Katsushima U, et al. Among authors: yamanaka y. Jpn J Clin Oncol. 2025 Jan 18:hyaf009. doi: 10.1093/jjco/hyaf009. Online ahead of print. Jpn J Clin Oncol. 2025. PMID: 39825794
Editorial overview: Nanobiotechnology for immunoengineering.
Gai A, Yamanaka Y. Gai A, et al. Among authors: yamanaka y. Curr Opin Biotechnol. 2025 Jan 9;91:103246. doi: 10.1016/j.copbio.2024.103246. Online ahead of print. Curr Opin Biotechnol. 2025. PMID: 39793265 No abstract available.
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).
Fukui T, Mamesaya N, Takahashi T, Kishi K, Yoshizawa T, Tokito T, Azuma K, Morikawa K, Igawa S, Okuma Y, Yamanaka Y, Hosokawa S, Kasai T, Masubuchi K, Nakamichi S, Aga M, Sasaki J, Kada A, Saito AM, Naoki K, Okamoto H; Thoracic Oncology Research Group (TORG). Fukui T, et al. Among authors: yamanaka y. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02548-6. doi: 10.1016/j.jtho.2024.12.027. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755169
Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia.
Katsushima U, Fukushima T, Nakano J, Ogushi N, Fujii K, Nagata Y, Kamisako K, Okuno Y, Okazaki Y, Nakanishi K, Yoshida K, Ikoma T, Takeyasu Y, Yamanaka Y, Yoshioka H, Hase K, Kurata T. Katsushima U, et al. Among authors: yamanaka y. Thorac Cancer. 2025 Jan;16(2):e15503. doi: 10.1111/1759-7714.15503. Epub 2024 Dec 9. Thorac Cancer. 2025. PMID: 39654007 Free PMC article.
999 results